A unit within the pharmaceutical company Alvogen recently presented arguments to the U.S. Supreme Court urging the rejection of a petition from a competitor. The case revolves around Alvogen’s intention to produce a generic version of a blockbuster IBS drug. Alvogen contends that the premise of the petition, which claims that the Federal Circuit exceeded its legal authority, is fundamentally flawed. For further information, please refer to the detailed report available on Law360.